BioCentury
ARTICLE | Company News

NPS submits Natpara BLA

October 25, 2013 1:10 AM UTC

NPS Pharmaceuticals Inc. (NASDAQ:NPSP) submitted a BLA to FDA for Natpara to treat hypoparathyroidism. The product is a recombinant human parathyroid hormone 1-84 (PTH). On Thursday, NPS was up $2.35 ...